Moderna, Inc. (NASDAQ:MRNA) Shares Acquired by Altshuler Shaham Ltd

Altshuler Shaham Ltd grew its holdings in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 184.8% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 18,800 shares of the company's stock after buying an additional 12,200 shares during the quarter. Altshuler Shaham Ltd's holdings in Moderna were worth $782,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in MRNA. Norges Bank bought a new stake in Moderna during the 4th quarter valued at approximately $163,833,000. FMR LLC lifted its position in Moderna by 7.4% during the fourth quarter. FMR LLC now owns 18,664,634 shares of the company's stock valued at $776,075,000 after buying an additional 1,282,469 shares during the period. Pictet Asset Management Holding SA boosted its holdings in shares of Moderna by 170.5% during the 4th quarter. Pictet Asset Management Holding SA now owns 1,766,398 shares of the company's stock valued at $73,447,000 after buying an additional 1,113,455 shares in the last quarter. Invesco Ltd. increased its stake in shares of Moderna by 24.3% in the 4th quarter. Invesco Ltd. now owns 5,006,462 shares of the company's stock worth $208,169,000 after acquiring an additional 979,858 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its position in Moderna by 225.7% during the 4th quarter. Renaissance Technologies LLC now owns 1,010,758 shares of the company's stock valued at $42,027,000 after acquiring an additional 700,458 shares during the period. 75.33% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

MRNA has been the subject of several recent research reports. Bank of America lowered their target price on shares of Moderna from $41.00 to $34.00 and set an "underperform" rating for the company in a report on Tuesday, February 11th. Morgan Stanley dropped their target price on shares of Moderna from $39.00 to $32.00 and set an "equal weight" rating on the stock in a report on Wednesday, April 9th. UBS Group dropped their price objective on shares of Moderna from $96.00 to $78.00 and set a "buy" rating on the stock in a report on Wednesday, February 19th. Berenberg Bank lifted their target price on Moderna from $33.00 to $42.00 and gave the stock a "hold" rating in a report on Thursday, January 16th. Finally, Barclays lowered shares of Moderna from an "overweight" rating to an "equal weight" rating and lowered their target price for the stock from $111.00 to $45.00 in a report on Tuesday, February 18th. Four research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $58.70.

Moderna Stock Performance

MRNA stock traded up $0.43 during trading on Tuesday, reaching $25.56. 1,666,163 shares of the company traded hands, compared to its average volume of 7,264,694. The company has a market capitalization of $9.88 billion, a price-to-earnings ratio of -2.76 and a beta of 2.23. The business has a 50 day simple moving average of $30.73 and a 200 day simple moving average of $39.25. Moderna, Inc. has a 12 month low of $23.15 and a 12 month high of $170.47.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.